The gains in the global fight against tuberculosis have been threatened as a result of the COVID-19 pandemic, including a diversion of resources that have led to disruptions in ongoing research and control programs.
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
Investigators conducted a study to determine the optimal fixed-dose combination of rifampicin/isoniazid/pyrazinamide in children with tuberculosis infection.
Researchers conducted a randomized trial that compared the effects of 3 treatment regimens for the prevention of tuberculosis infection among individuals with HIV infection currently taking antiretroviral therapy.
A recent trial compared the efficacy of standard oral therapy for pulmonary TB with a dry powder inhaler containing fixed doses of isoniazid, rifampicin, pyrazinamide, and levofloxacin.
Researchers studied patients with pulmonary tuberculosis to better understand the impact of sex on mortality and sputum microbiological status after treatment initiation.
